Express Pharma

Lincoln Pharma reports 57.85 per cent rise in standalone net profit at Rs 23.74 crore in Q2 FY23

The total income from operation for the quarter ending September 2022 reported at Rs 146.30 crore, higher by 12.54 per cent over Q1 FY23 total income from operation of Rs 130 crore

0 137

Lincoln Pharma has reported net profit for the quarter ending 30th September, 2022 at Rs 23.74 crore as against net profit of Rs 15.04 crore in Q1 FY23, growth of 57.85 per cent. The total income from operation for the quarter ending September 2022 reported at Rs 146.30 crore, higher by 12.54 per cent over Q1 FY23 total income from operation of Rs 130 crore, according to a company statement.

Further, the statement mentioned that the EBITDA for the quarter ending September 2022 was reported at Rs 34.59 crore as compared to Rs 23.41 crore in Q1 FY23 showing growth of 47.76 per cent. The EPS was reported at Rs 11.84 per share for Q2FY23 as compared to Rs 7.49 in the Q1 FY23 showing growth of 58.08 per cent. Shareholders approved a dividend of Rs 1.50 per share for the FY 21-22 at the 28th AGM held on 30th September, 2022.

Commenting on the results and performance, Mahendra Patel, Managing Director, Lincoln Pharma, said in the statement, “Company has delivered a robust operational and financial performance during t